建立加拿大纽芬兰和拉布拉多的区域毒品概况,使用急性药物死亡数据
Syed Z Raza1, Cindy Whitten1,2, Allyson Summers1
1Department of Research and Innovation, Newfoundland and Labrador Health Services, St. John's, Canada.
Clinical toxicology (Philadelphia, Pa.)
|July 28, 2025
概括
加拿大的药物死亡人数上升与多重药物毒性有关. 这项研究概述了纽芬兰和拉布拉多州的毒性,强调了针对兴奋剂和阿片类药物的有针对性降低危害策略的必要性.
科学领域:
- 公共卫生 公共卫生
- 毒理学 毒理学 毒理学
- 流行病学 流行病学
背景情况:
- 加拿大与毒品有关的死亡人数正在增加.
- 多种药物毒性,涉及多种药物类别,是这些死亡事故的主要驱动因素.
- 建立区域毒品概况对于有效的危害降低政策至关重要.
研究的目的:
- 建立纽芬兰和拉布拉多的区域药物概况,使用从急性药物毒性死亡的个体的毒理学数据.
- 确定导致这些死亡的最常见的药物和药物类别.
- 为减少危害的策略和政策制定提供信息.
主要方法:
- 利用了2018年至2023年间因急性药物毒性而死亡的个体的毒理学数据.
- 验尸医生确定了每个死亡事件中贡献的药物.
- 用描述性计数来识别流行药物和药物类别.
主要成果:
- 在纽芬兰和拉布拉多 (2018-2023) 共有222人死于非故意的急性药物毒性.
- 多种药物毒性占这些死亡的大多数 (55.4%).
- 兴奋剂 (特别是可卡因) 和阿片类药物是最常见的药物类别. 由于非药物类阿片类药物和阿片类药激剂治疗依赖症的死亡人数急剧增加.
结论:
- 兴奋剂的毒性,特别是可卡因的毒性,需要采取特定区域的降低危害措施.
- 涉及阿片类药物激动剂治疗成治疗的死亡人数的增加和非药物阿片类药物的出现需要紧急的政策关注.
- 实施药物检查服务可以加快创建药物概况,并更好地反映非致命的药物使用模式.
相关概念视频
Drug Concentrations: Measurements
602
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
602
Drug Regulation
1.8K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.8K
Pharmacovigilance
996
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
996
Drug Distribution: Overview
300
Drug distribution within the body is a dynamic process involving the movement of a drug in two directions across various compartments: from the bloodstream into tissues (tissue uptake) and from tissues back into the bloodstream (tissue release or redistribution). This process is passive and primarily driven by two variables: the concentration gradient between the bloodstream and the extravascular tissues and the drug's ability to cross the cell membrane.
Initially, the free drug in the...
Initially, the free drug in the...
300
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
126
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
126
Drug Control Governance: Regulatory Bodies and Their Impact
250
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
250


